Multicenter non-interventional post-authorization safety study (NI-PASS) to monitor the incidence of relevant and expected rare adverse events including lack of efficacy among CKD patients receiving s.c. Binocrit® or Epoetin alfa HEXAL® First published 30/12/2016 Last updated 28/04/2025 EU PAS number:EUPAS14525 Study Ongoing